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Objective: In this study, we aimed to investigate the presence of premenstrual syndrome
(PMS), primary dysmenorrhea (PD) and depression among women with ﬁbromyalgia (FM)
and  healthy females and to determine possible factors related with PMS and PD in FM.
Method: The present study was conducted on 98 female patients diagnosed with FM and
102  age and sex-matched healthy controls. All patients were evaluated for premenstrual
syndrome (PMS) and primary dysmenorrhea (PD). Premenstrual syndrome was assessed
among the patients for the presence of one or more affective or somatic symptoms within
the  ﬁve days preceding menses. The diagnosis of primary dysmenorrhea was deﬁned as hav-
ing  abdominal pain or lower back pain lasting at least two days during a menstrual period.
Dysmenorrhea was assessed via visual analog scale. Dysmenorrhea was rated via Multidi-
mensional Scoring System. The Hamilton depression scale was applied to all patients.
Results: Primary dysmenorrhea was established in 41% of FM patients and 28% of the control
group. A statistically signiﬁcant difference was found in PD between the two  groups (p = 0.03).
PMS was established in 42% of the FM patients and 25% of the control group. A statistically
signiﬁcant difference was found in PMS between the two groups (p = 0.03).
Conclusion: There is an increased frequency of premenstrual syndrome and dysmenorrhea
in  FM patients. The patients with high symptom severity scores and high depression scoresamong the FM patients are at risk of PMS and PD.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: drhterzi@yahoo.com (H. Terzi).
http://dx.doi.org/10.1016/j.rbre.2014.12.010
2255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(4):334–339 335
Avaliac¸ão  da  relac¸ão entre  síndrome  pré-menstrual  e  dismenorreia
primária  em  mulheres  com  ﬁbromialgia
Palavras-chave:
Fibromialgia
Síndrome pré-menstrual
Dismenorreia primária
Depressão
r  e  s  u  m  o
Objetivo: O objetivo deste estudo foi investigar a presenc¸a de síndrome pré-menstrual (SPM),
dismenorreia primária (DP) e depressão em mulheres com ﬁbromialgia (FM) e mulheres
saudáveis e determinar possíveis fatores relacionados com a SPM e DP na FM.
Método: Este estudo foi realizado com 98 pacientes do sexo feminino com diagnóstico de
FM  e 102 controles saudáveis pareados por idade e sexo. Todas as pacientes foram avaliadas
a  procura de síndrome pré-menstrual (SPM) e dismenorreia primária (DP). A síndrome pré-
menstrual foi determinada pela presenc¸a de um ou mais sintomas afetivos ou somáticos nos
cinco dias anteriores à menstruac¸ão. O diagnóstico de dismenorreia primária foi deﬁnido
como a presenc¸a de dor abdominal ou lombar com durac¸ão mínima de dois dias durante
o  período menstrual. A dismenorreia foi avaliada pela escala visual analógica. A dismenor-
reia  foi classiﬁcada pelo Sistema de Pontuac¸ão Multidimensional. A Escala de Depressão de
Hamilton foi aplicada a todas as pacientes.
Resultados: A dismenorreia primária foi encontrada em 41% das pacientes com FM e 28%
do  grupo controle. Encontrou-se diferenc¸a estatisticamente signiﬁcativa na DP entre os dois
grupos (p = 0,03). A SPM foi detectada em 42% das pacientes com FM e 25% do grupo controle.
Houve diferenc¸a estatisticamente signiﬁcativa na SPM entre os dois grupos (p = 0,03).
Conclusão: Há um aumento na frequência de síndrome pré-menstrual e dismenorreia
em  pacientes com FM. Aquelas com escore de gravidade dos sintomas elevado e altas
pontuac¸ões  de depressão entre as pacientes com FM estão em risco de SPM e DP.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
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habits, medications used, gynecological history (age of menar-ntroduction
ibromyalgia (FM) is a musculoskeletal condition character-
zed by widespread pain, tender points, fatigue, and the
bsence of another disease to explain all these symptoms.1
t is a condition that affects approximately 5% of the world
opulation and is particularly seen in women.2 In addition to
idespread pain; psychosomatic symptoms, sleep disorders,
ognitive dysfunctions, gynecological complaints, and sexual
ysfunctions may be seen in ﬁbromyalgia.3,4
Premenstrual syndrome (PMS) which repetitively occur
uring the luteal phase of the menstrual cycle is characterized
y the presence of physical and affective symptoms which
nterferes with daily life of a woman.5 Although its etiology
s unknown, genetic susceptibility, sensitivity to hormonal
hanges and altered brain processes are considered to be
esponsible.6,7 In addition, gonadal hormones are also known
o be modify central neurotransmitter activities such as sero-
onin and gamma aminobutyric acid (GABA); therefore, such
lterations may be involved in the underlying pathogenesis of
he disease.8,9
Primary dysmenorrhea (PD) which increased prostaglandin
evels or prostaglandin sensitivity may occur, which result in
yometrial contraction, ischemia, sensitivity in the pain ﬁb-
ils and pelvic pain, ultimately.10
Premenstrual syndrome and PD are common gynecologi-
al conditions in sexually active women. Several psychological
actors and increased central sensitization are accountablefor the etiopathogenesis of PMS and PD, as is the case for
ﬁbromyalgia.11–16
There is a limited number of studies investigating a pos-
sible relationship between ﬁbromyalgia and PMS  and PD in
the literature.15,17 In this study, we  aimed to investigate the
presence of PMS, PD and depression among women  with FM
and healthy females and to determine possible factors related
with PMS and PD in FM.
Materials  and  methods
The present study was conducted on 98 female patients diag-
nosed with FM and 102 age and sex-matched healthy controls.
The study was designed as a prospective case-control study.
The study protocol was approved by the Ethics Committee of
the institution. The study included female patients between
the ages of 20 and 45 with regular menstrual periods. The
women who were pregnant and menopausal, had a known
psychiatric or gynecological condition or previous surgery, and
the women with a disease preventing communication (men-
tal retardation), who were using oral contraceptives, and who
had a severe systemic disease were excluded from the study.
A detailed medical history was obtained and physical exam-
inations were performed on all patients. Demographic data,che, duration of menstrual cycle, duration and amount of
bleeding, and parity) were recorded for all patients. Physical
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the control group, indicating a statistically signiﬁcant differ-
ence (p < 0.05). The tender point count was 13.15±2.2 in the
patients with FM,  compared to 3.57 ± 1.6 in the control group.
Table 1 – Demographic data and number of tender points
and depression in both groups.
Fibromyalgia
n  = 98
Control group
n = 102
p  value
Age 35.9 ± 5.2 36.01 ± 4.8 0.70
BMI (kg/m2) 28.1 ± 4.23 28.3 ± 4.01 0.70
Curent smoker, n
(%)
48 (49%) 52 (51%) 0.10
Education level, n
(%)
0.30
Elementary
school
55 (56%) 65 (64%)
Middle/high
school
35 (36%) 37 (35%)
University 8 (8%) 10 (1%)
Employment
status, n (%)
0.09
Housewife 70 (71%) 74 (72%)
Employed 28 (29%) 28 (28%)
Regular physical
exercise, n (%)
28  (29%) 30 (30%) 0.50
Number of tender
points
13.15  ± 2.2 3.57 ± 1.60 0.01*
*336  r e v b r a s r e u m a t
examinations and investigations were performed during the
ﬁrst three days of the menstruation.
Diagnosis  of  ﬁbromyalgia
The diagnosis of FM was based on the 2010 American College
of Rheumatology (ACR) FM diagnostic criteria (2010 ACR FDC).
The symptom severity scores of the patients were recorded
based on 2010 ACR criteria.18 Examination of tenders points
(18 in total) was performed by palpation in accordance with
the 1990 criteria of the ACR.19 Digital palpation was performed
with an approximate force of 4 kg. The painful point count was
recorded. The patients who were diagnosed with FM at least
six months prior were included in the study.
Premenstrual  syndrome  assessments
Premenstrual syndrome was assessed by the presence of one
or more  affective (e.g. social withdrawal, confusion, anxi-
ety, irritability, angry outbursts, or depression) or somatic
(e.g. swelling of extremities, headache, abdominal bloating,
or breast tenderness) symptoms within the ﬁve days preced-
ing menses. Whether the symptoms recurred between days
4 and 13 of the cycle leading to impaired daily functions
was also assessed. The symptoms were conﬁrmed based on
prospective symptom ratings in two cycles. Other underlying
pathologies were also investigated to avoid misdiagnosis.20,21
Diagnosis  of  primary  dysmenorrhea
The presence of dysmenorrhea was examined in all patients.
The diagnosis of primary dysmenorrhea was deﬁned as hav-
ing abdominal pain or lower back pain lasting at least two
days during a menstrual period. Patients with dysmenor-
rhea for six months were considered positive. Dysmenorrhea
was  assessed by Visual Analog Scale (VAS). Dysmenorrhea
was rated through the Multidimensional Scoring System. The
Multidimensional Scoring System, previously developed by
Andersch and Milsom,22 was used to assess pain intensity
among patients. Based on this system, pain levels are deﬁned
based according to the criteria listed below:
1. Mild dysmenorrhea: painful menses that do not limit or
hinder normal daily activities, and which result in little or
no systemic symptoms and/or analgesic need.
2. Moderate dysmenorrhea: painful menses that slightly limit
or hinder normal daily activities, and which result in mod-
erate systemic symptoms and/or analgesic need.
3. Severe dysmenorrhea: painful menses that severely limit
or hinder normal daily activities, result in visible symp-
toms (such as fainting, vomiting, etc.), and respond poorly
to analgesics.
Depression
The Hamilton depression scale was applied to all patients. The
Hamilton depression rating scale (HAMDS), which was ﬁrst
developed by Hamilton,23 is a scale that assesses the patient’s
level of depression. Akdemir et al.24 previously performed the
validity and reliability study for the Turkish version of the 0 1 5;5 5(4):334–339
HAMDS. The HAMDS includes a total of 17 question items,
and the highest score that can be obtained is 53. In this scale,
a score of 7 or less is indicative of the lack of any signs relating
to depression; a score between 8 and 16 is indicative of mild or
moderate depression; and a score of 17 or above is indicative
of severe depression.
Statistical  analysis
Data were expressed in mean ± standard deviation. The
parametric data of the patients were compared through a
t-test, while non-parametric data were compared through
Chi-square test. A p value of ≤0.05 considered statistically
signiﬁcant.
Results
The mean age of the patients included in the study was
35.9 ± 5.2 years compared to 36.01 ± 4.8 years in the con-
trol group. No statistically signiﬁcant difference was found
between the groups in terms of age, BMI, habitual activi-
ties, educational status, marital status, occupational status,
and physical exercise (p > 0.05) (Table 1). Forty-nine percent
of the FM patients and 51% of the control group had a his-
tory of smoking. No participants used alcohol in either group.
The duration of FM was 12 ± 3.2 months. The mean HAMDS
score was 16.1 ± 7.12 in FM patients, compared to 8.2 ± 3.9 inHAMDS scores 16.07 ± 7.12 8.22 ± 3.9 0.01
BMI, body mass index; HAMDS, Hamilton depression rating scale.
∗ p < 0.05.
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Table 2 – The number of both groups of dysmenorrhea,
premenstrual syndrome and gynecological history.
Fibromyalgia
n  = 98
Control group
n = 102
p value
Menstrual volume,
n (%)
0.30
Mild 40 (40%) 44 (43%)
Moderate 36 (37%) 40 (40%)
Severe 22 (23%) 18 (17%)
Duration of
menstrual cycle
(days)
29.01  ± 1.23 28.76 ± 1.45 0.50
Duration of
menstruation
(days)
5.47 ± 1.42 5.28 ± 1.72 0.08
Parity, n (%) 0.60
Nulliparous 12 (12%) 12 (12%)
Multiparous 86 (88%) 90 (88%)
Method of delivery,
n (%)
0.80
Normal
delivery
66 (67%) 64 (63%)
Cesarean
section
32 (33%) 38 (37%)
Age of menarche 12.47  ± 1.38 12.36 ± 1.22 0.40
Primary
dysmenorrhea, n
(%)
40  (41%) 29 (28%) 0.04*
Mild 18 (45%) 15 (52%)
Moderate 19 (47%) 10 (34%)
Severe 3 (8%) 4 (14%)
Dysmenorrhea
VAS score
7.2  ± 2.3 5.1 ± 2.8 0.04*
Premenstrual
syndrome, n (%)
42 (42%) 25 (25%) 0.03*
VAS, Visual Analog Scale.
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eral quantitative sensory tests were performed to assess the∗ p < 0.05.
he difference was statistically signiﬁcant (p < 0.05). However,
here was no statistically signiﬁcant difference between two
roups in terms of menstrual volume, duration of menstru-
tion, delivery method, parity, and age of menarche (p > 0.05)
Table 2).
Of the patients with FM,  41% were diagnosed with PD which
as rated as mild in 18 (45%) patients, moderate in 19 (47%)
atients, and severe in three (8%) patients. Among the con-
rols, PD was established in 28% which PD was rated as mild
n 15 (52%) patients, moderate in ten (34%) patients, and severe
n four (14%) patients in the control group. A statistically sig-
iﬁcant difference was found in PD between the two groups
p = 0.03). The dysmenorrhea VAS value was 7.2 ± 2.3 in the FM
roup compared to 5.1 ± 2.8 in the control group, leading to a
igniﬁcant difference (p < 0.05) (Table 2).
Among FM patients and healthy controls, PMS was estab-
ished in 42% and 25%, respectively. A statistically signiﬁcant
ifference was found in PMS  between the two groups (p = 0.03).
he group with FM was divided into two groups based on
he presence of PD and PMS.  The symptom severity score of
he FM and PD (+) group was 8.7 ± 2.2 compared to 4.5 ± 1.8 in 5;5 5(4):334–339 337
the FM and PS (−) group. The tender point count was 14.8 ± 3.5
in the FM and PD (+) group compared to 11.8 ± 2.4 in the PD
(−) group. The Hamilton depression score was 19.0 ± 4.5 in
the FM and PD (+) group compared to 14.0 ± 3.5 in the PD
(−) group. A statistically signiﬁcant difference was found in
symptom severity score, tender point count, and Hamilton
depression score between the two groups, whereas there was
no statistically signiﬁcant difference in terms of age, BMI,
smoking, and duration of FM diagnosis (Table 3).
The symptom severity score of the FM and PMS  (+) group
was 9.9 ± 5.2 compared to 5.2 ± 2.3 in the FM and PMS  (−)
groups. The tender point count was 13.6 ± 3.6 in the FM and
PMS  (+) groups compared to 12.7 ± 4.3 in the PMS  (−) group.
The Hamilton depression score was 19.0 ± 7.4 in the FM and
PMS  (+) groups compared to 12.9 ± 4.3 in the PMS  (−) group. A
statistically signiﬁcant difference was found for the symptom
severity score and Hamilton depression score between the two
groups, whereas there was no statistically signiﬁcant differ-
ence in tender point count, age, BMI, smoking, and duration
of FM diagnosis (Table 4).
Discussion
In the present study, PMS and PD were statistically higher in
the FM patients compared to the control group. HAMDS scores
were also statistically signiﬁcantly higher in the FM patients
compared to the control group. In FM patients, HAMDS  scores
and symptom severity scores were statistically signiﬁcantly
higher in those diagnosed with PD and PMS  compared to those
without these diagnoses. In the present study, PMS  was estab-
lished in 42% of the FM patients. In the literature, 15–20% of the
menstruating women were reported to have PMS.25 In addi-
tion, PMS is a condition assessed within the scope of central
sensitivity syndromes.26 Chae et al.27 found a reduction in the
pressure pain threshold at acupuncture points in the women
with high symptom severity scores in premenstrual syndrome
compared to those with low scores. Amital et al.15 investigated
the similarities between premenstrual dysphoric disorder and
FM syndrome, and found higher levels of tender points and
higher rates of psychiatric comorbidities in the patients with
PMS.  Five of 30 patients with premenstrual dysphoric disorder
were diagnosed with FM.  In the present study, the depres-
sion scores were signiﬁcantly higher in the FM patients with
PMS  compared to those without PMS. Furthermore, the tender
point count was observed at higher rates in the group with FM
and PMS  compared to those without PMS; however, no statis-
tically signiﬁcant difference was found. Yunus analyzed two
studies and indicated a primary dysmenorrhea prevalence of
48% in a total of 103 patients with FMS from all studies.12,28
In the present study, premenstrual primary dysmenorrhea
was established in 41% of the FM patients. There is central
hypersensitivity to noxious and non-noxious stimuli in FM.18
In primary dysmenorrhea, hyperalgesia – especially in the
deep tissues – during the menstrual cycle has been shown
as evidence for the presence of central sensitization.13,29 Sev-presence of the central sensitization in women with primary
dysmenorrhea. In these studies, the pain sensitivity to var-
ious stimuli in different phases of the menstrual cycle was
338  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(4):334–339
Table 3 – Comparison of with or without a diagnosis of primary dysmenorrhea in patients diagnosed with ﬁbromyalgia.
Fibromyalgia group
n = 98
Patients  with PD
n = 40 (41%)
Patients without PD
n = 58 (59%)
p  value
Age 35.6 ± 7.2 36.2 ± 2.4 0.14
BMI (kg/m2) 27.9 ± 3.2 28.4 ± 5.2 0.25
Curent smoker, n (%) 22 (22%) 26 (26%) 0.52
Time since Fibromyalgia diagnosis (months) 13.1 ± 4.2 12.4 ± 3.7 0.28
Number of tender points 14.83 ± 3.52 11.81 ± 2.47 0.03*
Symptom severity score 8.73 ± 2.23 4.53 ± 1.85 0.01*
HAMDS score 19.02 ± 4.51 14.03 ± 3.52 0.03*
BMI, body mass index; HAMDS, Hamilton depression rating scale.
∗ p < 0.05.
Table 4 – Comparison of with or without a diagnosis of premenstrual syndrome in patients diagnosed with ﬁbromyalgia.
Fibromyalgia group
n = 98
Patients  with PMS
n = 42 (42%)
Patients without PMS
n = 46 (58%)
p  value
Age 35.8 ± 5.1 36.2 ± 3.1 0.10
BMI (kg/m2) 27.4 ± 7.2 28.8 ± 3.1 0.40
Curent smoker, n (%) 22 (22%) 26 (27%) 0.10
Time since ﬁbromyalgia diagnosis (months) 11.8 ± 3.7 11.9  ± 3.7 0.20
Number of tender points 13.6 ± 3.6 12.9 ± 4.3 0.10
Symptom severity score 9.97 ± 5.2 5.27 ± 2.3 0.01*
HAMDS score 19.0 ± 7.4 12.9 ± 2.7 0.03*
BMI, body mass index; HAMDS, Hamilton depression rating scale.
∗ p < 0.05.evaluated in women with and without dysmenorrhea. The
pain threshold against pressure,13 heat,14 and electricity15
were reduced in the abdomen, back, and extremities in
the menstrual phase in dysmenorrheic patients, whereas it
increased against cold. In one study, increased amplitude by
CO2 laser evoked cerebral potential in these patients.14 In the
study by Soyupek et al.,17 the frequency of FM in primary
dysmenorrhea was 15.6%. They observed that the somatic
symptoms and symptom severity scores were higher in the
patients with primary dysmenorrhea and FM compared to
the PD patients without FM.  Similarly in the present study,
symptom severity scores and depression scores were higher
in the PD patients with FM compared to those without PD. In
the present study, the ﬁnding toward the statistically signiﬁ-
cantly higher rates of PD PMS  and higher depression scores
in FM than the control group supports the hypothesis that
these conditions may have some common grounds in the
etiopathogenesis. In the present study, the depression score
was statistically higher in the FM group compared to the con-
trol group. The comorbidity of FM was demonstrated with
many  psychiatric conditions such as depression, panic dis-
order, anxiety, and posttraumatic stress disorder. Although
the relation between depression and FM has not been exactly
understood, it is believed that chronic pain may cause depres-
sion, and also the chronic pain syndromes may be a variant
30of depression. The relation between pain and depression
is highly complex and is associated with many  factors. The
mode of stimulus, sex, emotional status, and the medica-
tions used are involved in this interaction.31 In the presentstudy, depression scores and symptom severity scores were
higher in the group with premenstrual syndrome and dys-
menorrhea among the FM patients. As the coexistence of
other painful conditions with FM may increase the depression
scores, the occurrence of other symptoms may also be due to
the increased central sensitization in the patients with high
symptom severity scores. Well-designed further studies are
required in this matter. The studies demonstrated that sen-
sory stimuli causing pain were lower in the depressed patients
compared to the control group.32 The higher depression scores
and also the higher VAS scores, especially in patients with FM,
suggested that there might be a reduction in the pain thresh-
old in this group of patients.
The present study is limited to be a cross-sectional study
with a limited number of populations. Whether the patholo-
gies examined in the study were present prior to the diagnosis
of FM was not investigated.
In conclusion, there is an increased frequency of pre-
menstrual syndrome and dysmenorrhea in FM patients. The
patients with high symptom severity scores and high depres-
sion scores among the FM patients are at risk of PMS  and PD.  It,
hence, suggests that there may be common etiopathological
mechanisms among these medical conditions. However, fur-
ther large scale studies are required to conﬁrm these ﬁndings.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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